Citigroup
GTBP icon

Citigroup’s GT Biopharma GTBP Stock Holding History

Citigroup’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,781
Closed -$2.18K – 6123
2025
Q4 		$2.18K Buy
+2,781
New +$1.98K ﹤0.01% 5443
2022
Q3 		– Sell
-6
Closed -$1K – 6025
2022
Q2 		$1K Sell
6
-15
-71% -$1.14K ﹤0.01% 6026
2022
Q1 		$2K Sell
21
-131
-86% -$11.6K ﹤0.01% 6061
2021
Q4 		$14K Buy
152
+83
+120% +$12.4K ﹤0.01% 5488
2021
Q3 		$14K Sell
69
-135
-66% -$40.6K ﹤0.01% 5371
2021
Q2 		$95K Buy
+204
New +$84.8K ﹤0.01% 4530

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Citigroup's GTBP Position: Q1 2026 in Review

Citigroup sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 2,781 shares — an estimated $2.18K sold.

Citigroup first reported a position in GTBP in Q2 2021 and held it in 6 quarters. The position peaked at $95K in Q2 2021. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Citigroup reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 2,781 GT Biopharma shares in Q1 2026, an estimated $2.18K.
  • Citigroup first reported a position in GT Biopharma in Q2 2021 and held it in 6 quarters.
  • Citigroup's GT Biopharma position peaked at $95K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.